Home
Cytopoint Efficacy
Use of Cytopoint in the Allergic Dog
Gober M, Hillier A, Vasquez-Hidalgo MA, Amodie D, Mellencamp MA
Frontiers in Veterinary Science, 2022;9:909776
PMC9343842 · DOI: 10.3389/fvets.2022.909776

Prospective study · n=62 dogs · 26 breeds · Age range 6 months-12 years (mean 5.77 yrs)
60% seasonal allergies · 30% non-seasonal · Malassezia resolved prior to entry
47%
Success in 24hrs
94%
Success Day 7
98%
Success Day 28
100%
Success Day 56
92%
50% Lesion Reduction
Why this matters for bulldog owners: Cytopoint breaks the scratch-infection cycle by targeting IL-31, the primary itch cytokine. The study required Malassezia to be cleared before entry, confirming that pruritus management is a separate therapeutic goal from infection treatment. For bulldogs with atopic dermatitis driving recurrent yeast, Cytopoint addresses the upstream cause of barrier disruption.
Treatment Success Rate Over Time
Owner-Assessed Pruritus Score (PVAS) Over Time
Pruritus Management Approaches Compared
Data sourced from Gober et al. 2022 (PMC9343842). This visualization is for educational purposes only. Treatment success defined as owner-reported PVAS improvement meeting predefined threshold. Individual results may vary. All treatment decisions should be made with a licensed veterinarian.